# Dexcom Leads FDA TEMPO Pilot for Expedited Digital Health Device Evaluation

> news · REPORTED · 2026-08-02

Dexcom was identified as a lead participant in the FDA's TEMPO pilot program, a new regulatory pathway designed to improve and expedite the evaluation process for digital health devices. The pilot reflects broader FDA efforts under new HHS leadership to review and modernize device authorization categories.

About Dexcom: Dexcom is a medical device company specializing in continuous glucose monitoring systems and digital health tools for diabetes management.

- Company: Dexcom
- Sector: digital health
- Primary source: https://www.kelp.nyc/briefing/digital-health/2026-07-27

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.